Home › Chronic Lymphocytic Leukemia › NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin. Exclusion Criteria: * There are no exclusion criteria for this study.
About the study
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following:
Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)
What is being tested
- Long-Term Follow-Up of Participants who Received CAR-T cells (other)
Sponsor: Medical College of Wisconsin · Participants: 500 · Started: Dec 1, 2017
Contact the study team
- Medical College of Wisconsin Clinical Cancer Center · Phone: 414-805-8900
Official record on ClinicalTrials.gov — NCT03375619
Locations in the U.S.
| Wisconsin | Froedtert Hospital & Medical College of Wisconsin, Milwaukee |
Conditions
- Chronic Lymphocytic Leukemia
- B-Cell Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Burkitt Lymphoma
- Multiple Myeloma
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.